US Representative

Andy Harris Authored & Sponsored Legislation

Session

Co-Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB627

Introduced
1/22/25  
Ensuring Accurate and Complete Abortion Data Reporting Act of 2025This bill requires states, as a condition of federal payment under Medicaid for family planning services, to report certain abortion data to the Centers for Disease Control and Prevention (CDC). (Currently, reporting is voluntary.) The CDC must develop standardized questions for states with respect to specified variables (e.g., maternal demographics and methods of abortion).
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB629

Introduced
1/22/25  
Ending Chemical Abortions Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB632

Introduced
1/22/25  
Protecting Life on College Campus Act of 2025This bill prohibits the award of federal funds to an institution of higher education (IHE) that hosts or is affiliated with a school-based service site that provides abortion drugs or abortions to its students or to employees of the IHE or the site. An IHE that hosts or is affiliated with a site must, in order to remain eligible for federal funds, annually certify that the site does not provide abortion drugs or abortions to students or employees.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB645

Introduced
1/23/25  
National Constitutional Carry Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB679

Introduced
1/23/25  
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB682

Introduced
1/23/25  
Heartbeat Protection Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB685

Introduced
1/23/25  
Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB686

Introduced
1/23/25  
Protecting the Dignity of Unborn Children Act of 2025 This bill establishes a new federal criminal offense for recklessly disposing of or abandoning fetal remains in a landfill or in any navigable waters of the United States.The term fetal remains means any part (except a cremated part) of a deceased human fetus following an abortion.A violator is subject to a fine, up to three years in prison, or both.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB687

Introduced
1/23/25  
MERIT Act of 2025 Modern Employment Reform, Improvement, and Transformation Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB699

Introduced
1/23/25  
No Taxpayer Funding for the U.N. Population Fund ActThis bill prohibits the use of funds to provide contributions directly or indirectly to the United Nations Population Fund (UNFPA). The UNFPA is the United Nations sexual and reproductive health agency.